论文部分内容阅读
美国纽约消息:对常用抗溃疡性结肠炎(UC)药物柳氮磺胺吡啶(Sulfasalazine)治疗无效的大量UC病人口服一种试验性药物产生了效果。这一试验是在Mount Sinai医学中心进行的。据报道,轻度至中等度UC病人使用Olsalazine(Dipentum)后,3人中有一人减轻了症状。最近Pharmacia药厂向食品与药物管理局申请使用Dipentum。该药使进柳氮磺胺吡啶[即5-氨基水杨酸(5-ASA)]的活性部分进入靶器管结肠,不溶解于胃。 Olsalazine由两分子5-ASA组成,以偶氮键连接,去掉了柳氮磺胺吡啶的磺胺吡啶部分。即:
NEW YORK, USA - Oral administration of a test drug to a large number of UC patients who are refractory to the commonly used ulcerative colitis (UC) drug sulfasalazine has had an effect. The trial was conducted at Mount Sinai Medical Center. It has been reported that one person out of three people has had symptoms relieved after using Olsalazine (Dipentum) in patients with mild to moderate UC. Pharmacia recently applied to FDA for Dipentum. The drug causes the active portion of sulfasalazine [5-aminosalicylic acid (5-ASA)] to enter the colon of the target vessel and not dissolve in the stomach. Olsalazine consists of two molecules of 5-ASA, azo bond, remove sulfasalazine sulfasalazine part. which is: